| 3.41 0.04 (1.19%) | 03-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.54 | 1-year : | 5.3 |
| Resists | First : | 3.89 | Second : | 4.54 |
| Pivot price | 2.89  |
|||
| Supports | First : | 2.56 | Second : | 1.75 |
| MAs | MA(5) : | 3.34 |
MA(20) : | 2.76 |
| MA(100) : | 4.14 |
MA(250) : | 16.48 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 87.9 |
D(3) : | 90 |
| RSI | RSI(14): 60.4 |
|||
| 52-week | High : | 305 | Low : | 1.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ HIND ] has closed below upper band by 12.2%. Bollinger Bands are 4.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.45 - 3.47 | 3.47 - 3.48 |
| Low: | 3.25 - 3.26 | 3.26 - 3.27 |
| Close: | 3.39 - 3.41 | 3.41 - 3.43 |
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.
Wed, 25 Feb 2026
Vyome Holdings Unit LiveChain to Acquire $5.8M Humanyze Notes, Issuing 25% Equity to Remus - TradingView
Tue, 24 Feb 2026
MIT-born Humanyze’s AI HR engine shifts as Livechain takes over operations - Stock Titan
Wed, 18 Feb 2026
Experimental eye drop for uveitis rivals steroids in tests, targets $3B - Stock Titan
Tue, 27 Jan 2026
Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study - Business Wire
Fri, 26 Dec 2025
What is the current Price Target and Forecast for Vyome Holdings, Inc. (HIND) - Zacks Investment Research
Fri, 05 Dec 2025
HIND Stock Price and Chart — NASDAQ:HIND - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 1.54e+006 (%) |
| Held by Institutions | 42.1 (%) |
| Shares Short | 75 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.63e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 508.9 % |
| Return on Equity (ttm) | -24.6 % |
| Qtrly Rev. Growth | 344590 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 260650 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|